Immunic (IMUX) Fundamental Analysis: Revenue, Earnings & Valuation

5.08 / 10

Netural

Fundamental rating is neutral with a 5.1/10 score. Strengths include strong cash‑to‑market and high inventory turnover. Weak points are low asset‑to‑market, revenue‑to‑market and a high income‑tax‑to‑profit ratio. Overall, fundamentals are modest, offering balanced potential.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight14.02%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.62%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight18.60%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.32%

1M Return-0.63%

PB-ROE

Value1.09

Score3/3

Weight29.17%

1M Return9.74%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-1.07%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.40%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight10.76%

1M Return4.32%

Asset-MV

Value-0.55

Score0/3

Weight7.30%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight16.52%

1M Return5.94%

Is IMUX fundamentally strong?

IMUX scores 5.08/10 on fundamentals and holds a Fair valuation at present. Backed by its -1653.15% ROE, 0.00% net margin, -1.58 P/E ratio, -23.04 P/B ratio, and 38.00% earnings growth, these metrics solidify its Netural investment rating.